drug

ALLO-329

1 story · latest Aug 12, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Allogene Therapeutics

Timeline

Allogene reports Q2 2026 results, cites ALPHA3 futility data and FDA designations for cema-cel

Aug 12Quarterly updateAllogene Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.